Skip to Content
Global News Select

Evotec Shares Jump After Sandoz Partnership Agreement

By Cecilia Butini

 

Shares in Evotec rose in early trading on Wednesday after the German biotechnology company said its Seattle-based subsidiary Just-Evotec Biologics would enter into a partnership with Novartis's Sandoz to develop and manufacture biosimilar medicines.

At 0747 GMT, Evotec shares were up 8.6% at EUR17.88.

The multiyear partnership agreement covers the development and manufacture of several biosimilar medicines and includes an option for expansion, Novartis said.

The partnership is an important validation of Just-Evotec Biologics, Jefferies analyst Peter Welford said in a note.

Evotec will receive a double-digit million dollar figure upfront and up to $640 million in future payments contingent on development progress, plus undisclosed milestones on commercial progress, the analyst said.

Importantly, Evotec could also receive future fee-for-service revenue plus royalties on biosimilars manufactured using its proprietary technology J.POD, Welford added.

 

Write to Cecilia Butini at cecilia.butini@wsj.com

 

(END) Dow Jones Newswires

May 10, 2023 04:18 ET (08:18 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.

Market Updates

Sponsor Center